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ABSTRACT 
 
The process of producing monoclonal antibodies using the hybridoma technology 
has been an arduous task for many years. In this study, we aim to improve the efficiency 
of monoclonal antibody production by isolating mature splenic B cells in advance of 
fusion using magnetic activated cell sorting (MACS) to select for cells expressing 
CD138, a cell marker present in mature B cells.  Pre-isolating a population of cells 
expressing CD138
+
 , but lacking CD19 and B220, resulted in a reduced number of cells 
required for fusion.   
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INTRODUCTION 
The overall objective of this study was to improve the efficiency of monoclonal 
antibody production by separating splenic B cells in advance of fusion. It was predicted 
that isolating mature B lymphocytes prior to the fusion would remove unwanted non-B 
cells, decrease the number of cells to be fused, and reduce the number of irrelevant 
hybridomas, thereby increasing efficiency and reducing laborious screening.  The 
isolation of B lymphocytes was done using magnetic activated cell sorting (MACS) while 
selecting for CD138
+ 
cells, a marker for mature B cells. 
The commercially available CD138
+
 Plasma Isolation Kit used for this 
experiment allowed for the isolation of cells expressing CD138 while expressing low 
amounts of CD45R (B220)
 
and CD19.  CD 138 is a heparin sulfate-rich integral 
membrane proteoglycan found on the surface of epithelial cells in mature mouse tissues, 
which actively participates in cell binding and cell signaling. This marker also behaves as 
a matrix receptor for interstitial collagens, fibronectin, and thrombospondin. When B 
lymphocytes emigrate to the peripheral circulatory system, expression of CD138 is 
temporarily lost, then it is re-expressed when B lymphocytes differentiate into 
plasmablasts and plasma cells, the desired stage for hybridoma production. CD19 is a 
protein expressed on immature B cells. Upon maturation into plasma cells, the presence 
of CD19 is lost. CD 45R (B220) is an isoform of the CD45 protein present on B 
lymphocytes throughout their development. Similar to CD19, expression of B220 
decreases as cells differentiate into plasma cells. Using the CD138
+
 Plasma Isolation Kit, 
it was possible to isolate a population of mature B cells that also produce antibodies. Pre-
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isolating a population of cells expressing CD138
+
 , but lacking CD19 and B220, resulted 
in a reduced number of cells required for fusion.   
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BACKGROUND 
 
Monoclonal Antibody Production 
Therapeutic monoclonal antibodies generated using hybridoma technology first 
entered clinical studies in the 1980s (Reichert and Rosenweig, 2005). As of 2005, more 
than 150 monoclonal antibody products had been introduced into clinical studies. In their 
1975 journal article describing the development of the hybridoma technology, Kohler and 
Milstein discussed the difficulty in producing antigen-specific monoclonal antibodies.  In 
Kohler and Milstein’s first experiment, only 3% of the hybrid clones were found to be 
antigen-specific.  In their second experiment, the percentage of antigen-specific clones 
reduced to only 0.2% (Kohler and Milstein, 1975). From these numbers, it was clear that 
obtaining a hybrid cell that produces antibodies against a specific antigen is very difficult 
and infrequent; approximately 1 in 10
6
 cells (Margulies, 2005).  Since 1975, researchers 
have tried to improve the efficiency of monoclonal antibody development using 
techniques to isolate antigen-specific B cells prior to the fusion. Such techniques were 
expected to reduce the number of irrelevant hybridomas produced from the fusion, thus 
reducing laborious screening (Napaporn et al., 2009). A number of these techniques 
involve using isolation methods based on cell surface Ig expression. These techniques 
include capturing B cells on an antigen-coated solid matrix, using flow cytometry with 
fluorescently labeled antigen, and rosetting with magnetic particles or antigen-coated red 
blood cells (Kodituwakku et al., 2003).  
Isolating antigen-specific B cells is an arduous task, as the number of such cells is 
less than 1% of the total number of plasma cells (Alkan, 2004). The success of an 
isolation can be evaluated by measuring the cell viability, reproducibility, yield, and 
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purity of the isolated B cells (Kodituwakku et al., 2003). The yield can be defined as the 
percentage of antigen-specific cells isolated from the initial number of cells.  Purity can 
be defined as the percentage of antigen-specific B cells from the population of B cells. A 
problem that occurs with determining purity is distinguishing between specific versus 
non-specific B cell binding to the antigen.  In order to overcome this obstacle, scientists 
have looked for methods to confirm specific binding. To date, no technique has been 
developed which allows for the isolation of a pure antigen-specific B cell population 
without also including non-specific B cells (Kodituwakku et al., 2003).  
 
Isolation of Antigen-Specific B Cells Using Columns and Plates 
One of the first attempts of isolating antigen-specific B cells was performed in 
1968 using an antigen-coated solid matrix (Wigzell and Anderson, 1968). Wigzell 
isolated B cells by passing cells from the lymph node of an immunized mouse through an 
antigen-coated plastic bead column (Wigzell and Anderson, 1968). Using this procedure, 
Wigzell obtained yields of 60-95%. Specificity of the isolated B cells was determined 
using the haemolytic plaque assay developed by Neils Jerne. The purity of the isolated 
cell population was not determined for this experiment. After removing the bound cells 
from the column, it was found that the cell viability had reduced.  Further analysis of the 
isolated cell population showed that although the column had been successful in isolating 
antigen-specific B cells, large amounts of non antigen-specific cells were also included.  
In 1993, Steenbakkers et al. used a variation of this technique to develop hybridomas 
(Steenbakkers et al., 1993). Steenbakkers immunized mice with HIV antigens. Isolation 
of the B cells was done by panning antigen-coated culture plates. The isolated cell 
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population was then fused to myeloma cells and cultured. The yield and purity of this 
experiment were calculated to be 5% and 24%, respectively. Subsequently, De Wildt et 
al. isolated antigen-specific B cells from patients diagnosed with systemic lupus 
erythematosus (SLE) (De Wildt et al., 1997). De Wildt incubated U1 ribonucleoprotein  
(U1 RNP) auto antigen-specific B cells in U1 RNP-coated wells, and used trypsin to 
remove the bound cells. The cells were then harvested and studied. Unfortunately, 
analysis of the supernatant revealed that only 0.5 to 1.5% of the antibody secreted by the 
isolated cells was specific to U1 RNP.  The low purity could result from the presence of 
non-specific binding of cells to the coated wells in the final isolated population. Thus, 
although use of an antigen-coated solid matrix can isolate antigen-specific B cells, 
experiments using this technique have not excluded non-specific binding cells. 
 
Isolation of Antigen-Specific B Cells Using FACS 
In the 1970’s, a new technique using fluorescent labeled antigens to isolate 
antigen-specific B cells was developed by Julius et al.  In their experiment, spleen cells 
from limpet haemocyanin (KLH) immunized mice were labeled using 
immunofluorescence, then separated using flow cytometry (Julius et al., 1972). This 
technique is also termed fluorescence activated cell sorting (FACS).  Analysis of the 
isolated B cell fraction indicated that 40–52% of the fluorescent-conjugated KLH 
antigen-binding cells had been isolated.  However, purity was not measured in this study, 
indicating the possibility of a large number of non-specific binding cells being included 
in the isolated population. Hoven et al. (1989) used this FACS technique to isolate 
ovalbumin (OA)-specific B cells from immunized mice. The yield of this isolation was 
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1% and the purity was 42% (Hoven et al., 1989). After performing an ELISPOT analysis 
on the supernatant, it was found that only 20-50% of the isolated antigen-specific B cells 
produced antibody.  In another experiment, Mcheyzer-Williams et al. (2000) used the 
same technique to study memory B cell development and maintenance by isolating 
memory B cells from immunized mice that expressed B220 and CD138 (Mcheyzer-
Williams et al., 2000).  After isolation of CD138
+
 B cells using flow cytometry, 
ELISPOT assays showed that only 55% of the isolated CD138
+
 antigen-specific B cell 
population secreted antigen-specific antibodies. Though the yield was not calculated, 
McHeyzer-Williams concluded that if the results of the ELISPOT reflected the actual 
purity of the isolated B cell population, this percent of purity is low (Kodituwakku et al., 
2003).  Thus, like the previous column and coated well techniques, flow cytometry has 
the ability to isolate antigen-specific B cells from the initial cell population but still does 
not produce high yield or purity.  
 
Isolation of Antigen-Specific B Cells Using Rosetting 
The use of rosetting with antigen-coated red blood cells began in the 1970’s 
(Kodituwakku et al., 2003). This technique involves incubating lymphocyte cells with 
antigen coated red blood cells to form rosettes. Rosetted cells are then separated from the 
remaining cell population by means of sedimentation. In an experiment performed by 
Brody, spleen cells and bone marrow cells from mice were incubated with red blood cells 
from sheep (Brody, 1970). Rosettes were isolated using sedimentation, and the specificity 
of the isolated B cells was confirmed using haemolytic plaque assays. Neither the yield 
nor the purity were determined, but it was concluded that rosetting with antigen-coated 
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red blood cells was not a very effective method of isolating cells due to the difficulty of 
separating rosetted cells from the non-rosetted cells even after sedimentation 
(Kodituwakku et al., 2003).  In 1977, Walker et al. modified the rosetting technique, 
using negative selection to remove non-antigen-specific cells from the initial population 
(Walker et al., 1977).  This modification resulted in rosettes being formed around the non 
antigen-specific B cells. Walker’s technique proved to be advantageous as it allowed for 
antigen-specific cells to be isolated without having to bind to other cells to form rosettes.  
 
Isolation of Antigen-Specific B Cells Using Rosetting and Magnetic Fields 
Since the 1980’s, antigen-coated magnetic particles have replaced the red blood 
cells in a new rosetting technique. This magnetic technique involves forming rosettes 
using immunomagnetic beads, then uses a strong magnetic field to separate the rosetted 
cells from the non-rosetted cells (Kodituwakku et al., 2003). Egeland et al. first used this 
technique in 1988 to isolate rheumatoid factor (RF)-positive B cells from the blood of 
patients diagnosed with rheumatoid arthritis and from normal patients (Egeland et al., 
1988). Egeland used magnetic particles to form rosettes with the RF specific B cells. 
Despite the low number of RF-specific cells in the body, using the immunomagnetic 
beads produced a high yield of RF positive cells. In addition, analysis by ELISA 
indicated that more than 92% of the isolated cells produced RF antibodies. In 1995, Irsch 
et al. developed a new technique called magnetic activated cell sorting (MACS) which 
allowed for the isolation of rare antigen-specific B cells (Irsch et al., 1995). In this 
experiment, cells were labeled with antibodies along with magnetic microbeads and 
phycoerythrin. Magnetic columns were used to separate the antigen-specific binding cells 
 13 
and results were analyzed using flow cytometry.  Using this procedure resulted in a purity 
of 75%; yield was not calculated. A few years later, in 1999, Leyendeckers et al. isolated 
memory B cells from immunized humans using a two step process involving MACS 
followed by flow cytometry. By using a combination of the two techniques, 
Leyendeckers was able to obtain a yield of 98% and a purity of 10% (Leyendeckers et al., 
1999).   
Thus, while rosetting techniques give a decent yield, a combination of MACS and 
flow cytometry have shown to give higher yields and purity.  Isolating antigen-specific B 
cells using just immunomagenetic methods had once been a satisfactory method; 
however, using magnetic cell sorting (MACS) followed by fluorescence activated cell 
sorting (FACS) has become an efficient and reliable method of isolating antigen-specific 
B cells (Kodituwakku et al., 2003). The procedure described by Leyendeckers et al. has 
proven to be an efficient way of obtaining both a higher yield and higher purity.  
However, even with a combination of these techniques, the highest reported purities are 
still not 100%, indicating that isolating pure antigen-specific B cells still remains a 
difficult task.  
 
Isolating Antigen-Specific B Cells Prior to Fusion 
Since the development of the hybridoma technology, attempts to improve the 
efficiency of monoclonal antibody production have been made by isolating antigen-
specific B cells prior to fusion. The solid matrices (columns or wells) and flow cytometry 
techniques used for this purpose are similar to those discussed above for isolating 
antigen-specific B cells after fusion.  Experiments performed using the three different 
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techniques have huge discrepancies when reporting purities. With respect to purity, 
initially, low purities were reported as scientists used plaque forming assays to determine 
the purity of the isolated B cell populations.  This assay can be used for determining 
antigen-specific B cell purity by counting the plaques that are formed when the antibody 
producing cells lyse the red blood cells. While the plaque forming assay ensures 
specificity, it is an inefficient method of determining purity since it is possible that only a 
small proportion of the isolated antigen-specific B cell population may differentiate into 
antibody secreting cells (Kodituwakku et al., 2003). Researchers have reported purities 
ranging from 0.5% to 88% when using the cell capture on antigen-coated solid matrix 
method.  Purities of 2.5% to 90%, and 0.1% to 100%, have been reported using flow 
cytometric cell sorting and rosetting techniques, respectively.  Such varied ranges in 
purity may be due to the differing methods used to calculate the purity of the isolated 
population or the variability of antigens being tested.   
Similarly, all three techniques have shown wide variations when reporting yields. 
Yields of 5% to 95% have been reported when using cell capture on an antigen coated 
solid matrix, and yields of 5% to 55%, and 0.1% to 98%, have been reported using flow 
cytometric cell sorting and rosetting techniques, respectively.  In addition, the 
characteristics of the different types of B cells may also have been a cause for such large 
discrepancies. For example, studies show that circulating B cells are not able to 
differentiate into plasma cells as quickly as marginal zone B cells (Kodituwakku et al., 
2003).  Hence, the type of B cell being used for each experiment should be taken into 
account when comparing the yield and purity obtained using the different techniques. 
Studies show that pre-enriching a population of antigen-specific B cells prior to fusion of 
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the B cells with myeloma cells does not necessarily increase the efficiency of the process, 
but does reduce downstream screening.  Despite the advancements in technology, 
isolating a population of pure antigen-specific B cells remains a difficult task and efforts 
are constantly being made to increase the yield and purity of the isolated B cell 
population.  
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PROJECT PURPOSE 
 
Using the solid matrix or flow cytometry techniques mentioned above, it is 
possible to isolate a population of antigen-specific B cells expressing a specific marker of 
interest.  Although a newer technique, magnetic activated cell sorting (MACS), has been 
used to isolate antigen-specific B cells after fusion, to our knowledge no study has tested 
whether isolating antigen-specific B cells by MACS prior to fusion increases the 
efficiency of the process or reduces downstream screening efforts.  In this study, the 
MACS principle was used to isolate plasma cells expressing CD138, a marker for mature 
B lymphocytes. It was predicted that isolating mature B lymphocytes in general (without 
isolating antigen-specific cells) prior to the fusion would significantly decrease the 
number of cells being fused, thereby increasing the efficiency of monoclonal antibody 
production, and potentially decreasing the downstream screening time. 
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MATERIALS AND METHODOLOGY 
 
1.1 Materials 
 
Mice 
BALB/cJ and A/J mice were purchased from The Jackson Laboratory (Bar Harbor, ME) 
and housed in the Abbott Bioresearch Center (ABC) animal facility. Immunizations were 
done following IACUC protocol #21. For the first fusion, mice were immunized with 
human IgG as a general immunogen to test mouse antibody formation against a human 
protein. For the second fusion, mice were immunized with 293 cells transfected with 
RON Delta 160 antigen.  
 
MACS 
The MACS CD138
+
 Plasma Cell Isolation Kit for mouse was ordered from 
Miltenyibiotec (Catolog no. 130-092-530). 
 
Other Reagents 
B220-Mouse CD 45R R-PE antibody (Caltag laboratories, CAT# RM 2604 
Lot#1389418B); Mouse CD19 FITC antibody (Caltag laboratories, CAT# RM 7701 
Lot#0600B); Rat anti mouse CD138 APC antibody (BD Pharmigen, CAT# 558626 
Lot#93862); R-PE conjugated affinity purified goat anti mouse IgG (1+2a+2b+3) Fc 
specific (Jackson ImmunoResearch, CAT #115-115-164 Lot#84859 ); Goat anti mouse 
Fc HRP (Immunopure, CAT #31439 Lot#JJ1172524 ); RPMI 1640 (Invitrogen CAT# 
11875-093); Fetal Clone 1 (Hyclone CAT# SH 30080-03 Lot# ANM 20274);Ultra low 
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IgG Fetal Bovine Serum (Invitrogen CAT#16250-078,Lot#1215199); Azaserine 
Hypoxanthine (SigmaCAT#A9666); TMB (3,3’,5,5’,Tetramethylbenzidine (Sigma 
CAT#T0440); 2N H2SO4 (VWR CAT# VW3500-1). 
 
1.2 Methodology 
 
1.2.1 Isolating CD138+ cells using Magnetic Activated Cell Sorting (MACS) 
 
Spleens from immunized animals were removed, and single cell suspensions were 
prepared and washed. Cells were counted using crystal violet and a hemocytometer. After 
resuspending 10
8 
cells in 400 ls of FACS buffer (PBS, 0.5% BSA, and 2 mM EDTA), 
100 l of Non-Plasma Cell Depletion Cocktail was added. Cells were mixed and 
incubated at 4-8
o
C for 10 minutes, washed by adding 0.5-1.0 ml of buffer, and 
centrifuged at 300xg for 10 minutes. Cells were re-suspended in 900 l of FACS buffer 
and 100 l of Anti-Biotin Microbeads were added, followed by incubation at 4oC for 15 
minutes. The cells were once again washed and resuspended in 500 l of buffer. The 
suspension was placed in an LD Column in the magnetic field of the MACS separator. 
The unlabeled cell fraction that passed through the column was collected. The eluent 
contained the pre-enriched plasma cells. This fraction was labeled LD Elution. 
Remaining pre-enriched plasma cells were collected by adding 2 ml of buffer to the 
column and collecting the eluent. To obtain the non plasma cells for the FACS analysis, 2 
ml of MACS buffer were pipetted into the column and the fraction was flushed out using 
a plunger. This fraction was labeled LD fraction. The fraction containing the pre-enriched 
plasma cells was centrifuged at 300xg for 10 minutes and resuspended in 400 L of 
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buffer. 100 L of CD138 Microbeads were added and the cell suspension was incubated 
at 4-8
o
C for 15 minutes. Cells were washed and resuspended in 500 l of MACS buffer. 
Cell suspension was applied onto an LS column and the unlabeled cells that passed 
through the column were collected. The column was washed by adding 1 ml of buffer and 
collecting the eluent. This fraction, labeled LS Elution, contained CD138
-
 cells. The 
column was then taken out of the magnetic field and placed on a suitable collection tube. 
2 ml of MACS buffer were added to the column and the fraction was flushed out using a 
plunger. This fraction, labeled LS Fraction, was expected to contain the CD138
+
 cells.  
 
1.2.2 Analysis of MACS Separation using FACS  
 
The various fractions collected from the MACS separation were screened using FACS. 
10
6 
spleen cells from each fraction were counted using trypan blue and a hemocytometer. 
Cells were then placed in eppendorf tubes containing 1 ml PBS with 1% rat serum. 10 l 
of diluted staining antibody were added to each fraction. Antibodies were diluted 1:100 in 
PBS. Four positive controls were used: cells only, cells with CD19-FITC, cells with 
CD138-APC, and cells with B220-PE. Fractions and positive controls were incubated at 
4
o
C for thirty minutes and then read using the FACS machine.  
 
1.2.3 Cell Fusion 
 
Spleens from immunized animals were removed and single cell suspensions were 
prepared.  SP2/0 myeloma cells were harvested from culture and washed.  Cells from 
each fraction and tumor cells were mixed in a ratio of 5 spleen cells to 1 SP2/0 cells. 
Cells were fused using 50% PEG 1000 using standard techniques (Kohler and Milstein, 
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1975). Fused cells were seeded in 96 well plates with selective media at various densities 
of spleen cells per well. Fusions were incubated at 37
o
C for 7-10 days.  When 
macroscopic colonies were observed, supernatants were removed and tested using ELISA 
and FACS. The amounts of spleen cells, Sp2 cells, PEG, and SFM used for each fusion 
are shown in Tables 3 and 4.  
 
1.2.4 Screening for Antigen Reactivity using ELISAs  
 
The supernatants from Fusion-1 were screened for specific reactivity using an ELISA. 
ELISA plates were coated with 100 l of 1.0 g/ml human IgG, incubated overnight at 
4
o
C, washed 3x with 200 l TPBS, and blocked in 5% non fat dry milk in TPBS at room 
temperature for 1 hour before the assay. Supernatants from fusion were diluted 1:3 
serially in PBS containing 1% BSA. After an hour of incubation at room temperature, the 
plates were washed three times with TPBS. 50 l of 1:10,000 diluted goat anti mouse Fc 
HRP secondary antibody were added to each well and incubated at room temperature for 
one hour. The plate was washed 3x in TPBS and 100 l of TMB substrate per well were 
added for colometric development for 5 to 10 minutes at room temperature. The reaction 
was stopped by adding 100 l of 2N H2SO4.  The OD 450nm was obtained by plate 
reader and data was recorded in notebook. 
 
1.2.5 Screening for Antigen Reactivity using Fluorescence Activated Cell Sorting 
(FACS)  
 
The supernatants from Fusion-2 were screened for antigen reactivity using FACS 
analysis. BaF3 cells were placed on 96-well plates and washed with PBS. Samples 
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(positive control antibodies and the supernatant from the fusions) were diluted 1:2 in PBS 
and incubated at 4
o
C for one hour. After primary antibody incubation, the cells were 
centrifuged, washed once with PBS, and incubated with 50 l of 2.0 g/ml PE-
conjugated affinity purified goat anti-mouse Fc specific antibody at 4
o
C for one hour. 
After secondary antibody incubation, the cells were washed once with PBS and 
suspended in 50 l of PBS/well. The plates were stored in 4oC until read using the FACS 
machine.  
 
1.2.6 Determining Mouse IgG Production of Hybridomas using ELISA 
 
The supernatants from Fusion-1 and -2 were screened for the presence of IgG using 
ELISAs. ELISA plates were coated with 100 l of 1.0 g/ml goat anti-mouse IgG 
overnight at 4
o
C ,washed 3x with 200 l TPBS, and blocked in 5% non fat dry milk in 
TPBS at room temperature for 1 hour before the assay. Supernatant from fusions were 
diluted 1:2 serially in PBS containing 1% BSA, beginning at 1:5 dilutions. After an hour 
of incubation at room temperature, the plates were washed 3x with TPBS. 50 l of 
1:10,000 diluted goat anti mouse Fc HRP secondary antibody were added to each well 
and incubated at room temperature for one hour. The plate was washed 3x in TPBS and 
100 l of TMB substrate per well were added for colormetric development for 5 to 10 
minutes at room temperature. The reaction was stopped by adding 100l of 2N H2SO4. 
The OD 450nm was obtained by a plate reader. 
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RESULTS 
 
The objective of this study was to improve the efficiency of monoclonal antibody 
production, or reduce downstream screening efforts, by isolating a subpopulation of 
antibody-producing plasma cells in advance of fusion.  CD 138 is a marker found on the 
surface of epithelial cells in mature tissues. CD138 is present when B cells differentiate 
from plasmablasts into plasma cells, thus CD 138 represents a marker for mature B cells 
(presumably those secreting antibody).  Using positive selection by magnetic activated 
cell sorting (MACS), CD138
+
 cells were isolated from the spleen, then fused with SP2 
myeloma cells. Fused cells, hybridomas, were cultured for two weeks and monitored for 
macroscopic colony growth, general IgG production, and reactivity to a specific antigen 
(when mice were pre-immunized). 
The success of the MACS separation was determined using cell counts and FACS 
analysis. Tables 1 and 2 show cell counts from two separations done using MACS.  In the 
first analysis (Table 1), 2.0 x10
8
 splenic cells were obtained from two spleens. After 
labeling the cells with Non-Plasma Cell Depletion Cocktail (to remove non-plasma cells), 
Anti-Biotin microbeads, and passing the suspension through an LD column, 8.6 x10
6   
pre-enriched general plasma
 
cells were obtained.  This represents 4.3% of the original 
number of cells. Labeling the pre-enriched plasma cells with CD138 microbeads and 
passing the suspension through a LS column, resulted in
 
0.5 x10
6 
cells being obtained. 
This number is 0.25% of the original population of cells. Similar to the first analysis, the 
final fraction of the second analysis (Table 2) contained 0.27% of the starting number of 
cells. Both these analyses indicate that the majority of non-plasma cells and 
undifferentiated B cells were removed through the MACS separation.  
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Table 1: MACS Analysis Cell Count-1 
Fraction ID Cell Count % Total 
Starting 2.0 x10
8
 - 
LD Elution 8.6 x10
6
 4.3% 
LD Fraction 25 x10
6
 12.5% 
LS Elution 7.0 x10
6
 3.5% 
LS Fraction 0.5 x10
6
 0.25% 
Table 1 illustrates the cell counts from the first MACS analysis 
performed on splenic cells. The starting number of cells for this 
assay was 2.0x10
8
. The separation resulted in the isolation of 0.25% 
CD138
+
 cells from the entire population.  The LD fraction contains 
general plasma cells.  The LS fraction contains CD 138
+
 B cells. 
 
 
Table 2: MACS Analysis Cell Count-2 
Fraction ID Cell Count % Total 
Starting 1.12 x10
8
 - 
LD Elution 1.07 x10
7
 9.6% 
LD Fraction 4.9 x10
7
 43.8% 
LS Elution 4.0 x10
6
 3.6% 
LS Fraction 0.3 x10
6
 0.27% 
Table 2 illustrates the cell counts from the second MACS analysis 
performed on splenic cells. The starting number of cells for this 
assay was 1.12x10
8
. The separation resulted in the isolation of 0.27% 
CD138
+
 cells from the entire population. 
 
 
A FACS analysis was performed on the MACS purified cells to determine 
whether the MACS protocol successfully isolated CD138
+
 plasma cells from the entire 
population of spleen cells (Figure-1). The outcome of the separation was compared with 
the outcome of the separation performed by Miltenyi Biotec (the same biotech company 
from which the MACS kit was purchased).  Panels A, B, and C are histograms from the 
separation done by Miltenyi Biotec, while D, E, and F were performed in-house.  Panels 
A and D are histograms from the starting cell fraction, the spleen cells before separation. 
When comparing A and D, it can be seen that only a portion of these starting cells 
express CD138
+
 (a marker for mature B cells) (X-axis), while a significant portion stain 
for CD45R (B220) (a marker for immature B cells) (Y-axis).  In addition, both panels 
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show a significant portion of cells staining negative for both CD138 and B220, which 
likely represent non-plasma cells.  Panels B and E denote the LD elution fraction 
containing pre-enriched plasma cells after depletion of B220 immature cells. As 
expected, these LD elution cells stained negative for B220 (Y-axis), while a small portion 
stained positive for CD138 (X-axis).  
 
Figure 1: FACS Analysis of the MACS Separations Using the CD138
+ 
Plasma Cell 
Isolation Kit.  The effectiveness of the MACS separation was determined by using 
FACS analysis on the various fractions. Panels A, B, and C show a FACS analysis 
performed by Miltenyi Biotec. Panels D, E, and F were performed in-house. In this 
experiment, CD19 was labeled with FITC, BD220 with PE, and CD138 with APC. The 
five fractions screened were: Initial Cells, LD elution, LD fraction, LS elution, and LS 
fraction.  Note the change in the axis labels between C and F.   
 
 
Panels C and F represent cells eluted from the LS column, and theoretically 
contain mature B cells.  The Miltenyi analysis shows these cells stain strongly for CD138 
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(X-axis) and lack CD19 (Y-axis) (a marker present on immature B cells, but lost when B 
cells mature into plasma cells). This data conflicts with the in-house analysis showing a 
mixture of CD138 positive and negative cells (Y-axis), and a mixture of CD19 positive 
and negative cells (X-axis).  This indicates the separation was successful in enriching the 
CD138
+
 cells compared to the starting population, but not successful in isolating a pure 
population of CD138
+
 cells. 
The various fractions from the separations were fused with myeloma cells and 
cultured.  From data shown in Table 3 and 4, it can be seen that using MACS to separate 
CD138
+
 cells (LS fraction) resulted in a decrease in the number of cells being fused. This 
decrease in the number of cells being fused led to a reduction in the quantities of 
materials used for the fusion. In a typical fusion, approximately 1.0 x10
8
 spleen cells 
would have been used. After isolating the CD138
+ 
plasma cells, 5.6 x10
6
 spleen cells 
were fused with 3.0 x10
6 
SP2 myeloma cells (Table 3). In fusion-2, 1.0 x10
7 
CD138
+ 
cells 
were fused with
 
5.0 x10
6
 myeloma cells (Table 4).  These numbers of SP2/0 cells were 
chosen to maintain a 5:1 ratio of spleen cells to myeloma cells. Fusing a population of 1.0 
x10
8 
spleen cells with the SP2 tumor cells would require approximately 1ml of PEG. 
After the separation, the amount of PEG required reduced to only 50 l, and 83 l, for 
fusion-1 and -2, respectively. In addition, a normal fusion of 1.0 x10
8
 cells requires 
approximately 20-30 plates being seeded and screened. By fusing a smaller population of 
cells, less screening was required as only 5-7 plates were plated.  Thus, separating 
CD138
+
 B cells from remaining plasma cells before fusion reduces the amount of 
materials used for the fusion. 
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Table 3: Materials Used for Fusion-1 
Fraction ID Cell # Sp2 Cell # PEG (ul) SFM 
Starting 3.6 x10
7
 1.8 x10
7
 200 4 ml 
LD Fraction 3.0 x10
7
 1.5 x10
7
 200 4ml 
LS Elution 3.0 x10
7
 1.5 x10
7
 200 4ml 
LS Fraction 5.6 x10
6
 3.0 x10
6
 50 950 ul 
Shown in Table 3 are the amounts of spleen cells, SP2 myeloma cells, PEG, and 
SFM used for Fusion-1. Four fractions were fused: Starting (plasma and non 
plasma cells), LD Fraction (pre enriched plasma cells), LS Elution (CD138
-
 
plasma cells), and LS Fraction (CD138
+
 plasma cells). 
 
 
Table 4: Materials Used for Fusion-2 
Fraction ID Cell # Sp2 Cell # PEG (ul) SFM (ml) 
Starting 3.0 x10
7
 1.5 x10
7
 166 4 
LS Elution 3.0 x10
7
 1.5 x10
7
 166 4 
LS Fraction (0.5x10
6
) 1.0 x10
7
 5.0 x10
6
 83 1 
LS Unfused 1.0 x10
6
 - - - 
Shown in Table 4 are the amounts of spleen cells, Sp2 cells, PEG, and SFM used 
for Fusion 2. 5 fractions were fused: Starting (plasma and non plasma cells), LS 
Elution (CD138
-
 plasma cells) LS Fraction (CD138
-
 plasma cells), and LS 
Unfused (CD138
+
 plasma cells that were not fused with sp2 cells). 
 
 
After the fusion procedure, the hybridomas were incubated at 37
o
C with 5% CO2 
for two weeks. During this incubation period, macroscopic cell colony growth was 
monitored at various points. The amount of growth in each fraction as well as the 
concentration resulting in optimal growth was observed. The cell growth for Fusion-1 is 
shown in Table 5. Seven days post fusion, 288 wells were screened in the fraction 
labeled “Starting”. Of the 288 wells, only 37 (12.8%) contained macroscopic colonies. 
However, 14 days post fusion, 150 colonies were observed in 288 wells (52.0%). In the 
LS Fraction (5 x10
5
), 95 out of 96 (98.9%) screened wells contained colonies 14 days 
post fusion. Interestingly, in the LS Fraction (5 x10
4
) plate, only 24 out of 96 wells 
(23.9%) contained colonies. While most of the fractions experienced a dramatic increase 
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in the number of observable colonies between days 7 and 14, this increase was not seen 
in the LS Fraction (5 x10
4
) plate.  
Table 5: Colony Growth of Fused Cells from Fusion-1 
Fraction ID Number of Colonies (Day 7) 
+ growth in wells / total wells 
plated 
Number of Colonies (Day 14) 
+ growth in wells / total wells 
plated 
Starting 37/288 (12.8%) 150/288 (52.0%) 
LD Elution 32/288 (11.1%) 110/288 (38.2%) 
LS Elution 11/288 (3.8%) 136/288 (47.2%) 
LS Fraction (5 x10
5
) 73/96 (76.0%) 95/96 (98.9%) 
LS Fraction (5 x10
4
) 23/96 (23.9%) 24/96 (25.0%) 
Fractions were seeded in 96 well plates at various densities of spleen cells per 
well, and incubated at 37
o
C. The growth of macroscopic colonies was monitored 
8 and 15 days post fusion. 
 
Table 6 shows the various fractions plated for Fusion-2. In the “Starting” fraction, 26 
colonies were observed out of 288 plated wells (9.0%) at 14 days post fusion, which is 
substantially below the 52% observed for Fusion-1. In the LS elution plate (containing 
non-B cells), 0 colonies were observed even after 14 days. As a control experiment, 
unfused cells were plated to confirm the hypothesis that plama cells would not survive in 
the absence of fusion. As expected, no colonies were observed in the plate with unfused 
cells. Very few living cells could be found in this fraction.   In addition, five 
concentrations of the LS Fraction were plated to determine the concentration. 
that resulted in optimal hybridoma growth. In the LS Fraction (0.5x10
6
), 0 colonies were 
observed 14 days post fusion (Table 6), which is substantially lower than observed for 
Fusion-1 with the same number of cells.  However, plating the cells in concentrations of 
1x10
5 
and 2x10
4
 resulted in 7 and 4 colonies, respectively. Plating the cells at 
concentrations lower than 2x10
4 
resulted in no colony growth.  
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Table 6: Colony Growth of Fused Cells from Fusion-2 
Fraction ID Number of Colonies (Day 14) 
+ growth in wells / total wells 
plated 
Starting 26/288 (9.0%) 
LS Elution 0/288 
LS Unfused 0/96 
LS Fraction (0.5x10
6
) 0/96   
LS Fraction (1 x10
5
) 7/96 
LS Fraction (2x10
4
) 4/96 
LS Fraction (4 x10
3
) 0/96 
LS Fraction (8 x10
2
) 0/96 
Fractions were seeded in 96 well plates, at a various densities of 
spleen cells per well, and incubated at 37
o
C. The growth of macro-
scopic colonies was observed 14 days post fusion. Plating of the 
unfused cells as well as plating cells with low density (10
3 
and10
2
) 
resulted in no growth. 
 
To determine the fused cells’ abilities to produce antibodies, an IgG ELISA was 
performed on supernatants from both fusions (Table 7). Only two fractions were tested 
for this experiment. Out of 95 tested wells in the “Starting” fraction, only 9 wells (9.4%) 
contained IgG-producing hybridomas, while 8/23 wells (34.7%) of the LS fraction (5x10
4
 
cells) contained IgG-producing hybridomas.  
 
Table 7: ELISA Screening for IgG Producing and Antigen Reactive Hybridomas 
Fraction ID IgG Producing Human Antigen 
Reactive 
mAb Candidates 
Starting 9/95 (9.4%) 4/95 (4.2%) 4/9 (44.4%) 
LD Elution - 8/95 (8.4%) - 
LS Elution - 0/95 (0.0%) - 
LS Fraction-5x10
5
 - 38/95 (40.0%) - 
LS Fraction-5x10
4
 
(24 wells) 
8/23 (34.7%) 5/23 (21.7%) 5/8 (62.5%) 
Table 7 shows the results from the IgG ELISA and the human antigen specific 
ELISA. Hybridomas from Fusion-1 were used for this assay. 9 hybridomas were 
IgG producing and 4 were antigen reactive in the Starting fraction. The LS 
Fraction with 5x10
4 
cells/well plate contained 8 IgG producing and 5 antigen 
reactive hybridomas. Determination of positive and negative hybridomas was 
done by comparing the OD450 of the positive control to the remaining wells.
 
 
 29 
Because it was not known whether the hybridomas were producing IgG, or if the 
unfused spleen cells had produced IgG during the two week incubation period, 23 
colonies from the LS Fraction-5x10
4
 were selected and transferred to a new plate and 
cultured. Out of the 23 screened wells, 8 were IgG producing hybridomas. This 
confirmed that the hybridomas were producing the IgG and not the unfused spleen cells.  
           Experiments were also designed and performed to test the antibody’s ability to 
react with a specific antigen. For Fusion-1, the mice were immunized with human IgG as 
a general immunogen to test mouse antibody formation against a human protein. The 
hybridoma antibodies abilities to react to human IgG was tested using an ELISA. The 
results of this experiment are shown in Table 7, third column. In the Starting plate, 4 out 
of 95 tested wells (4.2%) contained antibody-producing cells that reacted with human 
IgG. The LD Elution fraction contained 8 antigen reactive wells out of 95 (8.4%) 
screened wells. This increase in number was expected as the LD Elution Fraction 
contained pre-enriched plasma cells. No antigen-reactive colonies were observed in the 
LS elution fraction, containing predominantly CD138
-
 plasma cells. Both concentrations 
of the LS Fractions contained antigen reactive colonies. In LS Fraction-5x10
5
, 
approximately 40%
 
of the cells were reactive to the human antigen. This increase in 
reactivity was expected as the LS Fraction contained only mature B cells and the chances 
of obtaining an antigen specific hybridoma were higher.  Hybridomas were labeled as 
“positive” for IgG production and antigen reactivity if their OD450 was similar to that of 
the positive control. Figures 2 and 3 are examples of plates that were screened using 
ELISAs.  
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Figure 2: ELISA Screening for IgG Producing Hybridomas 
 
Figure 2 shows the results from the IgG ELISA performed on hybridomas from 
Fusion-1. The Starting fraction is shown in this figure. Positive cells were 
determined by comparing the OD450 of the positive control (row S1 column-12) 
to the remaining wells. The positive control had an OD450 of approximately 
0.300. In this specific ELISA, wells with OD450 above 0.200 were considered 
to be potential antibody producing hybridoma candidates. 
 
 
Figure 3: ELISA Screening for Antigen Reactive Hybridomas 
 
Figure 3 shows the results from the ELISA used to screen for antigen reactive 
hybridomas. The Starting fraction from Fusion-1 is shown in this figure. 
Positive cells were determined by comparing the OD450 of the positive control 
(row S1 column12) to the remaining wells. In this case, the positive control 
had an OD450 of approximately 0.500. Wells with OD450 above 0.290 were 
considered to be potential antigen reactive hybridoma candidates. 
 
1 3 5 7 9 11 S1 
S6 0.0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
O D 450n m 
Columns 
Rows 
ELISA Screening for Antigen Reactive Hybridomas  
(Starting Plate) 
1 3 5 7 9 11 S1 
S6 0 
0.1 
0.2 
0.3 
0.4 
Columns 
Rows 
ELISA Screening for IgG Producing Hybridomas  
in 96 well plates (Starting Plate) 
OD 450nm 
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          Similar experiments as mentioned above were also performed for Fusion-2 (Table 
8).  For the second fusion, mice were immunized with 293 cells pre-transfected with 
RON Delta 160 antigen. Unlike the first fusion, this fusion was not as successful in 
producing antigen-specific hybridomas, and growth was slow. All fractions from Fusion-
2 were screened using ELISAs for undesirable mouse IgG Production. The Starting plate 
and the LS Fraction (0.5x10
6
) plate showed that approximately 50% of the screened wells 
contained undesirable mouse IgG-producing hybridomas, indicating that in this fusion-2 
experiment pre-selecting for CD138
+
 mature B cells did not increase the percent of 
successful hybridoma production. In the LS Fraction (1 x10
5
) plate (containing CD138
+
 
cells), only 7 out of the 95 (7.3%) screened wells were undesirable mouse IgG-producing 
hybridomas. However, once again, it was not clear whether this was a result of the 
hybridoma producing the IgG, or if the spleen cells had produced IgG during the two 
week incubation period.  In addition to examining undesirable mouse IgG production, the 
hybridoma’s ability to react to the RON Delta 160, the antigen the mice vaccinated with, 
was tested using FACS on BaF3 cells expressing the antigen on the surface (Table 8, 
third column).  In this experiment, unfortunately the fractions did not contain any 
antigen-reactive hybridomas. 
 32 
 
Table 8: ELISA and FACS Screening for IgG-Producing  
and Antigen-Specific Hybridomas
 
Fraction ID 
IgG Producing 
(ELISA) 
Antigen Reactive 
(FACS) 
Antibody 
Candidates 
Starting 51/95 (53.6%) 0/95 0/95 
LS Unfused Cells 1/95 (1.0%) 0/95 0/95 
LS Elution 7/95 (7.3%) 0/95 0/95 
LS Fraction (0.5x10
6
) 53/95 (55.7%) 0/95 0/95 
LS Fraction (1 x10
5
) 7/95 (7.3%) 0/95 0/95 
Table 8 shows the results from the IgG ELISA and the 293 RON Delta 160 FACS 
analysis on BaF3 cells. Hybridomas from Fusion 2 were used for this assay. In this 
ELISA, every plate had at least one IgG producing hybridoma. The Starting fraction and 
the LS Fraction (0.5x10
6
) showed approximately 50% of screened wells contain IgG 
producing hybridomas. In the LS Fraction (1 x10
5
), only 7 out of the 95 screened wells 
were IgG producing hybridomas. IgG positive hybridomas were determined by 
comparing the OD450 of the positive control to the remaining wells. None of the IgG 
producing hybridomas were antigen reactive when analyzed using FACS. Antigen 
reactive hybridomas were determined by comparing the FL2GeoMeans of the positive 
control to the remaining wells. 
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DISCUSSION 
 
The objective of this study was to improve the efficiency of monoclonal antibody 
production by pre-isolating a subpopulation of antibody producing plasma cells prior to 
fusion using magnetic activated cell sorting. While the data from Fusion-1 and Fusion-2 
are not consistent as to whether using MACS to separate the CD138
+
 cells results in an 
increase in the number of antigen-specific hybridomas, it is clear that this technique has 
both its advantages and disadvantages.  
Using MACS to separate CD138
+
 B cells was shown in this project to decrease 
the total number of cells required for fusion, and decrease the quantities of materials 
needed for the fusion. In addition, it is less tedious and more cost efficient to screen only 
3 plates to obtain 5 possible hybridoma candidates for scale up and mass production, as 
opposed to screening 60 plates and obtaining only 10 possible hybridoma candidates for 
antibody production.  Thus, regardless of whether the purification process alters the 
percent of fused cells, the MACS CD138
+
 procedure reduces reagent usage, and greatly 
decreases the number of plates required for screening. 
However, this procedure does have its disadvantages. As seen from the FACS 
analysis data, the CD138
+
 Plasma Cell Isolation Kit did not successfully select for only 
CD138
+
 cells based on the in-house FACS analysis. A significant portion of cells 
expressing CD19 (an immature B cell marker) were also included in the final isolated 
population (Figure 1).  Since CD19 is also a B cells marker, it was expected that a few 
cells expressing low levels CD19 would also be present in the purified cell fraction. In 
addition, cells expressing B220 (another marker for immature B cells) were also present 
in the final fraction (data not shown).  However, the isolation kit did successfully enrich 
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the population of cells expressing CD138. The difference in results of CD138
+
 isolated 
fraction may be due to a change in the MACS protocol; while the isolation kit by 
Miltenyi Biotec called for an MS column to isolate the CD138
+
 cells, an LS column was 
used instead in this study. The smaller MS column may have been more precise in 
selecting for CD138
+
 cells. 
The results from the experiments also suggest that the fusion of the CD138
+
 cells 
with myeloma cells does not always produce antigen reactive hybridomas. While 
experiments performed on supernatants from Fusion-1 provided promising results, this 
was not the case for Fusion-2. From the time of the original Kohler and Milstein’s study, 
it has been proven that each fusion is unique in that it can either produce many mAb 
candidates or can produce no candidates.  More repeats of these experiments need to be 
done to determine if the process of separating the CD138
+
 cells prior to fusion is 
worthwhile.  Further characterization of the hybridomas also needs to be done, including 
determining their isotypes, affinities, and epitopes. In addition, a replication of this 
experiment can also be performed on cells from bone marrow and lymph nodes to 
determine if the type of tissue being fused has an effect on cell growth, IgG production, 
and antigen reactivity.  
After performing two separations and two fusions, it was concluded that although 
this technique of separating the B cells before fusion does result in fewer number of cells 
being fused, it does not necessarily result in an increased number of IgG producing or  
antigen-reactive hybridomas. 
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